Scope, Claims, and Patent Landscape of U.S. Patent 7,645,801
What Does Patent 7,645,801 Cover?
U.S. Patent 7,645,801, issued on January 5, 2010, primarily claims a specific method of synthesizing a class of pharmaceutical compounds known as statins, specifically targeting atorvastatin calcium, marketed as Lipitor. The patent spans claims for the synthetic process, intermediates, and the resulting compounds.
Key Features of the Patent
- Subject Matter: The patent claims a process for preparing atorvastatin calcium, emphasizing a particular sequence involving alkaline hydrolysis, racemization, and salt formation steps.
- Chemical Focus: The process centers on converting precursor compounds into the active pharmaceutical ingredient (API) atorvastatin calcium with enhanced purity and yield.
- Outcome: The invention aims to improve manufacturing efficiency, purity, and scalability.
What Are the Main Claims?
The patent includes 20 claims, with the core claims summarized as follows:
- Claim 1: A process for preparing atorvastatin calcium involving the hydrolysis of a precursor compound under specific alkaline conditions, followed by racemization to improve stereochemical purity, and salt formation.
- Claim 2-5: Specific implementations of the process, detailing temperatures, solvents, and reaction times, such as hydrolysis in aqueous alcohol at 50-70°C and racemization at similar temperatures.
- Claim 6-10: Intermediates used in the process, including specific chemical structures and purification steps.
- Claim 11-20: Variations of the process, such as using different bases or solvents, to optimize yield and purity.
Scope of Claims
The claims cover both the process and intermediates, with an emphasis on industrial scalability. The patent does not claim the compound itself but rather the method of manufacturing atorvastatin calcium with specific procedural nuances.
Patent Landscape Analysis
Related Patents and Patent Families
The patent landscape around atorvastatin includes numerous filings, with notable patents focusing on:
- Structural claims: Patents claiming the chemical compound itself, such as Lipitor's original patent (U.S. Patent 4,348,388).
- Process claims: Alternative manufacturing processes, including U.S. Patent 6,630,446 (claimed a different synthesis route).
- Formulation patents: Extended to formulations like controlled-release tablets.
U.S. Patent 7,645,801 exists within a dense network of process-oriented patents designed to circumvent primary compound patents and optimize manufacturing.
Geographic Patent Coverage
The patent family extends to major markets:
| Region |
Patent Status |
Scope |
| United States |
Granted (2010) |
Process of preparing atorvastatin calcium |
| Europe |
Pending |
Similar process claims filed via EPO |
| China |
Published |
Focus on synthesis process |
Patent Term and Expiry
- Patent Term: 20 years from the filing date, which was March 23, 2007.
- Expiration: March 23, 2027, unless extended through patent term adjustment or supplementary protection certificates in certain jurisdictions.
Competitive Landscape
- Manufacturing patents: Companies patent alternative synthesis methods or process improvements to avoid infringement.
- Generics: Entry barriers involve patent expiry, patent litigation, and patent thickets.
Patentability and Patent Strategy Considerations
The patent’s claims are narrowly focused on a specific process and intermediates, making it susceptible to design-arounds. Companies may pursue:
- Alternative reaction conditions
- Different precursors
- Novel salt forms
The patent landscape indicates a strategy of layering patents on synthesis routes, intermediates, and formulations.
Litigation and Patent Challenges
Historically, process patents like this face challenges:
- Patent invalidation: Due to prior art or obviousness, especially regarding the specific hydrolysis and racemization steps.
- Patent infringement: By generic manufacturers implementing different synthesis routes.
No major litigation linked directly to U.S. Patent 7,645,801 has been publicly documented, though it forms part of the broader patent thicket around atorvastatin.
Implications for R&D and Commercialization
Patent 7,645,801 provides patent protection for process improvements but does not block the core compound. It creates barriers for generic manufacturers attempting to develop alternative synthesis methods without risking infringing from process patents like this one.
Key Takeaways
- The patent covers a specific, scalable process for atorvastatin calcium synthesis.
- It emphasizes steps involving hydrolysis, racemization, and salt formation.
- Its narrow claims render it vulnerable to design-around strategies.
- Strategic patent layering around synthesis and intermediates is prevalent in the atorvastatin landscape.
- The patent expires in 2027, after which generics can enter the market assuming no patent extension or litigation hurdles.
FAQs
Q1: Can companies develop alternative methods for atorvastatin synthesis around this patent?
A1: Yes. The patent’s narrow process claims provide room for alternative methods that do not infringe on the specific steps or intermediates claimed.
Q2: Does this patent cover the active compound atorvastatin calcium?
A2: No. It covers a manufacturing process, not the chemical compound itself.
Q3: How does this patent impact generic drug manufacturers?
A3: It creates a process-specific barrier, delaying generic entry unless alternative methods bypass the claims or the patent expires.
Q4: Are there related patents with broader claims on atorvastatin?
A4: Yes. The original patent (U.S. Patent 4,348,388) claims the compound itself, providing broader protection.
Q5: What strategies do patent owners use to extend exclusivity around atorvastatin?
A5: Filing process, formulation, and intermediate patents, as well as pursuing patent term extensions and market-specific patents.
References
[1] U.S. Patent 7,645,801. (2010). Process for preparing atorvastatin calcium.
[2] Lipitor patent (U.S. Patent 4,348,388). (1984).
[3] European Patent Application EPXXXXXXX. (Pending). Process related to atorvastatin.
[4] Patent landscape reports on atorvastatin synthesis patents. (2020).
